Summer Street Research Partners Announces Expansion of Research Team With Addition of Jim Molloy as Managing Director Covering Specialty Pharmaceuticals and Biotechnology

Jim Molloy joins Summer Street Research Partners covering specialty pharmaceuticals and biotechnology and adding significant experience to the SSRP research team.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend

Boston, Massachusetts (PRWEB) June 10, 2014

Summer Street Research Partners, a leading healthcare-focused investment bank, today announced that Jim Molloy has joined the firm’s research team as a Managing Director, covering the specialty pharmaceuticals and biotechnology sectors. He will be based in Boston.

“We are very excited to welcome Jim to the firm,” says Dr. Mark Landy, Director of Research. “Jim’s background and proven excellence in healthcare research strengthens our research mission of having a primary research expert opinion today on the most compelling healthcare topics of tomorrow.”

Jim brings 15 years of sell-side experience to Summer Street, having covered specialty pharmaceuticals and biotechnology for a diverse group of Wall Street investment banks. Prior to Summer Street, Jim was a Managing Director at Janney Montgomery Scott, with previous senior research positions at ThinkEquity Partners, Caris & Company, Oppenheimer, and Leerink Swann & Company. Jim has been ranked by Forbes Starmine for earnings accuracy. He earned an MBA from the F.W. Olin Graduate School of Business at Babson College and a BA from the University of Colorado, Boulder.

“I’m very excited to join Summer Street,” Jim says. "With our MCRI expert consulting network and singular focus on healthcare, I feel Summer Street is the perfect platform to add real value to institutional investors on important and timely healthcare topics.”

About Summer Street Research Partners

Summer Street Research Partners is an investment banking and securities firm focused exclusively on the healthcare sector. The firm is a trusted advisor to buy-side institutional clients and healthcare companies alike. Our vision is to help lead investment capital toward innovative products improving human life.